Stay updated on Fracture Risk Assessment in Osteoporotic Women Clinical Trial

Sign up to get notified when there's something new on the Fracture Risk Assessment in Osteoporotic Women Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fracture Risk Assessment in Osteoporotic Women Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the safety and efficacy of odanacatib in postmenopausal women with osteoporosis, specifically focusing on fracture risk reduction.
    Difference
    0.2%
    Check dated 2024-06-06T14:31:38.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying inclusion and exclusion criteria for postmenopausal women aged 65 or older with low bone mineral density. Previously, no information was provided in this section.
    Difference
    10%
    Check dated 2024-05-22T21:20:15.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:44:59.000Z thumbnail image

Stay in the know with updates to Fracture Risk Assessment in Osteoporotic Women Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fracture Risk Assessment in Osteoporotic Women Clinical Trial page.